Breaking News, Collaborations & Alliances

Advaxis Signs Licensing Deal with GBP

To develop and commercialize ADXS-HPV

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Advaxis, Inc. has entered into an exclusive licensing agreement with Global BioPharma, Inc. (GBP) for the development and commercialization of ADXS-HPV for the treatment of human papillomavirus (HPV)-associated diseases. GBP, a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC), was formed solely to focus on the development and commercialization of ADXS-HPV.   GBP plans to conduct registration trials with ADXS-HPV for the treatment of advanced cer...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters